Omeros Announces First Commercial Sales of YARTEMLEA®

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpati.

Business Wire • Jan 27, 2026

Omeros prices transplant complication drug at $36,000 per dose

Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a call with analysts on Wednesday.

Reuters • Jan 7, 2026

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Seeking Alpha • Jan 8, 2026

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Zacks Investment Research • Dec 29, 2025

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7,.

Business Wire • Dec 26, 2025

US FDA approves Omeros' drug to treat dangerous transplant complication

The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.

Reuters • Dec 24, 2025

Why Omeros Stock Skyrocketed Today

It won approval for a medicine that treats a potentially fatal complication from stem cell transplants. This is the first drug approved for that indication.

The Motley Fool • Dec 24, 2025

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef.

Business Wire • Dec 24, 2025

Gold Edges Lower; Omeros Shares Jump

U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday.

Benzinga • Dec 24, 2025

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation. Yartemlea is the first and only approved therapy for TA-TMA, showing high complete response rates and strong survival benefits in pivotal trials. I estimate Yartemlea's peak revenue potential at ~$300m, with commercialization pacing dependent on awareness, funding, and OMER's ability to scale.

Seeking Alpha • Dec 24, 2025